Kristen Stolka1, Paul Ndom2, Jennifer Hemingway-Foday3, Jeniffer Iriondo-Perez3, Wendell Miley4, Nazzarena Labo5, Jennifer Stella6, Mahamat Abassora7, Godfrey Woelk8, Robin Ryder9, Denise Whitby4, Jennifer S Smith10. 1. RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27709, United States. Electronic address: kstolka@rti.org. 2. SOCHIMIO, Rue EMIA, après Gendarmerie Nationale, Box 25513, Yaoundé, Cameroon. 3. RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27709, United States. 4. Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, BLDG 535, 4th floor, Frederick, MD 21702, United States. 5. Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, BLDG 535, 4th floor, Frederick, MD 21702, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, United States. 6. University of California, 55 Laguna Street, San Francisco, CA 94102, United States. 7. Expanded Program on Immunization, BP 186, Garoua, Cameroon. 8. Expanded Program on Immunization, BP 186, Garoua, Cameroon; Elizabeth Glaser Pediatric AIDS Foundation, 1140 Connecticut Avenue NW, Washington, DC 20036, United States. 9. University of California, 200 West Arbor Drive #8485, San Diego, CA 92103, United States. 10. 2103 McGavran-Greenberg, Department of Epidemiology, University of North Carolina at Chapel Hill, Campus Box 7435, Chapel Hill, NC 27599, United States.
Abstract
BACKGROUND: Individuals co-infected with Kaposi's sarcoma herpesvirus (KSHV) and Human Immunodeficiency Virus (HIV) are at greatly increased risk of developing Kaposi's sarcoma (KS). The objective of the current analysis is to identify risk cofactors for KS among HIV-positive individuals. METHODS: We conducted a case-control study of KS in Cameroon on 161 HIV-positive and 14 HIV-negative cases and 680 HIV-positive and 322 HIV-negative controls. Participants answered a physician-administered questionnaire and provided blood and saliva specimens. Antibodies against KSHV lytic, K8.1, and latent, ORF73, antigens were measured by ELISA to determine KSHV serostatus. Conditional logistic regression was performed to determine multivariate odds ratios (OR) and 95% confidence intervals (CI) for risk factors associated with KS among HIV-positive cases and controls. RESULTS: Overall, 98% (158) of HIV-positive cases, 100% (14) of HIV-negative cases, 81% (550) of HIV-positive controls, and 80% (257) of HIV-negative controls were KSHV seropositive. Risk factors for KS among HIV-positive individuals included KSHV seropositivity (OR=9.6; 95% CI 2.9, 31.5), non-use of a mosquito bed net (OR 1.9; 95% CI 1.2, 2.9), minority ethnicity (OR=3.1; 95% CI 1.1, 9.3), treatment from a traditional healer (OR=2.3; 95% CI 1.5, 3.7), history of transfusion (OR=2.4; 95% CI 1.5, 3.9), and family history of cancer (OR=1.9; 95% CI 1.1, 3.1). CONCLUSION: KSHV seroprevalence of ≥80% indicates a high prevalence in the general population in Cameroon. Among HIV-positive individuals, the strong association of KS with non-use of mosquito nets and treatment from traditional healers are compelling findings, consistent with recently reported data from East Africa.
BACKGROUND: Individuals co-infected with Kaposi's sarcoma herpesvirus (KSHV) and Human Immunodeficiency Virus (HIV) are at greatly increased risk of developing Kaposi's sarcoma (KS). The objective of the current analysis is to identify risk cofactors for KS among HIV-positive individuals. METHODS: We conducted a case-control study of KS in Cameroon on 161 HIV-positive and 14 HIV-negative cases and 680 HIV-positive and 322 HIV-negative controls. Participants answered a physician-administered questionnaire and provided blood and saliva specimens. Antibodies against KSHV lytic, K8.1, and latent, ORF73, antigens were measured by ELISA to determine KSHV serostatus. Conditional logistic regression was performed to determine multivariate odds ratios (OR) and 95% confidence intervals (CI) for risk factors associated with KS among HIV-positive cases and controls. RESULTS: Overall, 98% (158) of HIV-positive cases, 100% (14) of HIV-negative cases, 81% (550) of HIV-positive controls, and 80% (257) of HIV-negative controls were KSHV seropositive. Risk factors for KS among HIV-positive individuals included KSHV seropositivity (OR=9.6; 95% CI 2.9, 31.5), non-use of a mosquito bed net (OR 1.9; 95% CI 1.2, 2.9), minority ethnicity (OR=3.1; 95% CI 1.1, 9.3), treatment from a traditional healer (OR=2.3; 95% CI 1.5, 3.7), history of transfusion (OR=2.4; 95% CI 1.5, 3.9), and family history of cancer (OR=1.9; 95% CI 1.1, 3.1). CONCLUSION:KSHV seroprevalence of ≥80% indicates a high prevalence in the general population in Cameroon. Among HIV-positive individuals, the strong association of KS with non-use of mosquito nets and treatment from traditional healers are compelling findings, consistent with recently reported data from East Africa.
Authors: Denise Whitby; Vickie A Marshall; Rachel K Bagni; Wendell J Miley; Thomas G McCloud; Rebecca Hines-Boykin; James J Goedert; Betty A Conde; Kunio Nagashima; Judy Mikovits; Dirk P Dittmer; David J Newman Journal: Int J Cancer Date: 2007-01-15 Impact factor: 7.396
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Colleen Pelser; Carmelo Dazzi; Barry I Graubard; Carmela Lauria; Francesco Vitale; James J Goedert Journal: Ann Epidemiol Date: 2009-08 Impact factor: 3.797
Authors: J L Ziegler; R Newton; E Katongole-Mbidde; S Mbulataiye; K De Cock; H Wabinga; J Mugerwa; E Katabira; H Jaffe; D M Parkin; G Reeves; R Weiss; V Beral Journal: AIDS Date: 1997-11 Impact factor: 4.177
Authors: Joshua J Reece; Mark C Siracusa; Teresa L Southard; Cory F Brayton; Joseph F Urban; Alan L Scott Journal: Infect Immun Date: 2008-05-27 Impact factor: 3.441
Authors: Alison M Elliott; Denise Whitby; Robert Newton; Katie Wakeham; Emily L Webb; Ismail Sebina; Lawrence Muhangi; Wendell Miley; W Thomas Johnson; Juliet Ndibazza Journal: Infect Agent Cancer Date: 2011-09-30 Impact factor: 2.965
Authors: Amolo S Asito; Ann M Moormann; Chelimo Kiprotich; Zipporah W Ng'ang'a; Robert Ploutz-Snyder; Rosemary Rochford Journal: Malar J Date: 2008-11-18 Impact factor: 2.979
Authors: Elena M Cornejo Castro; Brian J Morrison; Vickie A Marshall; Nazzarena Labo; Wendell J Miley; Nathan Clements; George Nelson; Paul Ndom; Kristen Stolka; Jennifer J Hemingway-Foday; Mahamat Abassora; Xiaojiang Gao; Jennifer S Smith; Mary Carrington; Denise Whitby Journal: Genes Immun Date: 2019-05-20 Impact factor: 2.676
Authors: Nakougou Moϊ-Bohm Biatougou; Muriel S Ouedraogo; Serge Theophile Soubeiga; Theodora Mahoukede Zohoncon; Paul Ouedraogo; Dorcas Obiri-Yeboah; Aziz Sidi Aristide Tapsoba; Touwendpoulimdé Isabelle Kiendrebeogo; Tani Sagna; Pascal Niamba; Adama Traore; Jacques Simpore Journal: HIV AIDS (Auckl) Date: 2022-07-08
Authors: Elena M Cornejo Castro; Vickie Marshall; Justin Lack; Kathryn Lurain; Taina Immonen; Nazzarena Labo; Nicholas C Fisher; Ramya Ramaswami; Mark N Polizzotto; Brandon F Keele; Robert Yarchoan; Thomas S Uldrick; Denise Whitby Journal: Virus Evol Date: 2020-06-30